ET Capital is focused on liberating the talent of the entrepreneurs we back.
ET Capital Limited
15a Water Lane
+44 (0)1223 236632
Phico Therapeutics awarded up to $18.2 million (c.£13.2 million) CARB-X funding to advance SASPject antibacterial therapy through Phase 1 clinical trials.
FDA approves first ADC Therapeutics anti-cancer drug, ZYNLONTA™, for clinical use in patients with relapsed or refractory diffuse large B-Cell Lymphoma.